News about Market

Mankind Pharma Sees Margin Expansion, Chronic Segment Gains in Q3FY26

Mankind Pharma announced its consolidated financial results for the third quarter and nine months ended December 31, 2025, reporting steady growth driven by improved performance in its domestic pharmaceutical business and consolidation of its BSV portfolio.

Market | 04/02/2026 | By Darshana |  171

WHO, WTO and WCO Update Global Customs Codes to Fast-Track Vaccine Shipments by 2028

New customs codes under HS 2028 aim to improve global tracking and faster clearance of vaccines and essential medical supplies during health emergencies.

Market | 04/02/2026 | By News Bureau |  140

SanegeneBio Announces RNAi Global Licensing Collaboration with Genentech

SanegeneBio has licensed one of its RNAi programmes to Genentech in a global collaboration valued at up to USD 1.7 billion, including a USD 200 million upfront payment, milestone-based development and commercialisation payments, and tiered royalties. Genentech will oversee worldwide clinical development and commercialisation.

Market | 03/02/2026 | By News Bureau |  137

Agomab Unveils Plans for Initial Public Offering

Agomab has appointed JP Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen as joint book-running managers for the proposed Initial Public Offering (IPO), marking a key step in its plans to access the public markets.

Market | 03/02/2026 | By News Bureau |  142

Breakthru Medicine Raises USD 60 Million Series A to Advance Cancer Drugs

Founded by biotech veterans Steve Potts, Mark Mulvihill and Brian Barnett, Breakthru Medicine has raised USD 60 million in Series A funding to advance its stealth oncology pipeline, including molecular glues, small molecules and novel ADC payloads.

Market | 02/02/2026 | By News Bureau |  167

AstraZeneca Boosts Weight Management Portfolio via CSPC Collaboration

Under this agreement, Astrazeneca and CSPC Pharmaceuticals will initially progress four programmes, which utilise CSPC's advanced Artificial Intelligence (AI)-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.

Market | 31/01/2026 | By News Bureau |  242

Mabtech and Sai Life Sciences Partner to Advance Immunology Research

Under this collaboration, Mabtech and Sai will jointly deliver advanced immunology assay services — including high-sensitivity multiplex cytokine and phenotyping workflows — powered by the EYRA platform installed at Sai’s Boston discovery site.

Market | 31/01/2026 | By News Bureau

Concerto and Sacco System Sign Microbial Discovery Deal

Concerto and Sacco System aim to develop novel ingredients composed of synergistically interacting microbes with desirable functional properties.

Market | 30/01/2026 | By News Bureau |  100

AstraZeneca Commits USD 15 Billion to Expand Manufacturing and R&D in China

UK-based pharmaceutical major AstraZeneca has announced a USD 15 billion investment in China by 2030, marking its largest-ever commitment to the country. The investment is aimed at expanding the company’s research, development and manufacturing capabilities, reinforcing China’s role as a key pillar in AstraZeneca’s global growth strategy.

Market | 30/01/2026 | By Darshana |  119

Evestia Clinical Expands European Footprint with Acquisition of ICRC-Weyer

Evestia Clinical, a global independent specialist contract research organization (CRO), has announced the acquisition of Berlin-based ICRC-Weyer GmbH, a long-established CRO and scientific consultancy with strong expertise in data-driven clinical research.

Market | 29/01/2026 | By Darshana |  110